Latest Breaking News On - Minor species - Page 8 : comparemela.com

Anivive Awarded $500,000 Grant by the FDA for Canine Cancer Studies - Anivive is the first recipient to be awarded a MUMS grant during this round of funding - Funding will accelerate ongoing canine lymphoma studies - Anivive to initiate studies of verdinexor to treat other types of cancer News provided by Share this article Share this article LONG BEACH, Calif., July 8, 2021 /PRNewswire/ Anivive, a pet health technology company transforming the therapeutic discovery and development process, received $500,000 in grant funding to continue research on the use of LAVERDIA™ -CA1 (verdinexor) in the treatment of canine lymphoma. The grant was received from the U.S. Food and Drug Administration as part of the agency s Minor Use/Minor Species program, developed to support new animal drugs intended for uncommon or undertreated diseases such as canine lymphoma. Anivive was one of four companies selected for the grants.

Prnewswire aniviveDavid bruyetteCarrie woodAnivive lifesciences incMinor species animal health actDean for research drDrug administrationTufts universityDrug grant programMinor speciesAnivive chief medical officer david bruyetteAssociate deanCheryl londonCummings schoolVeterinary medicineGrant program